Boxing superstar Claressa Shields released a freestyle rap video on April 10, showcasing new skills and gaining traction ...

Shields called out Garcia for his use of a performance enhancing drug and for his pattern of abusive, defamatory and racist ...

Welsh boxing star Lauren Price has set her sights on a historic undisputed welterweight title clash with Mikaela Mayer, followed by a potential super-fight ...

Boxing. Deion Sanders lets guard down "fighting" with female boxer and learns his lesson Boxing. Claressa Shields shows proof of her innocence and explodes against those who want to sink her: Y ...

Claressa Shields has found herself at the center of an unexpected social media storm, and she isn't pulling any punches in ...

Dive into live coverage, expert insights, breaking news, exclusive videos, and more – plus, stay updated on the latest in current affairs and entertainment. Download now for all-access coverage ...

There was some meeting of boxing legends here in the one place at the one time as Claressa Shields speaks about it below. Greatest women’s boxer of all-time Claressa Shields met women’s boxing ...

Two women’s boxing legends met for the first time this weekend in the form of Claressa Shields and Katie Taylor, and they had an interesting chat. There is a big different in weight class but it ...

the preliminary nature of the Company's estimates of the charges and cash expenditures to be incurred in connection with the recent workforce reduction; the Company may not realize the benefits ...

As of December 31, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling $171.4 million and $303.5 million, respectively. Research and development ...

and provides an overview of recent and upcoming business highlights. "Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in ...

We expect our R&D expenses to continue to decrease overall in the 1H of 2025 due to our recent restructuring and as we complete Phase 2 trials for several indications and focus our ongoing ...